Peter R. Carroll, MD, MPH, Taube Family Distinguished Professor in Urology, Department of Urology at the University of California, San Francisco, outlines detection and treatment options for biochemical recurrence following a prostatectomy or radiation therapy. He details how recurrence can be detected with PSMA PET imaging, as the majority of cases have PSMA-avid lesions present. Dr. Carroll further notes typical and atypical regional and local areas of recurrence. He also describes a new disease management algorithm for deciding between further radiation therapy or monitoring & localized treatment.Read More
Peter R Carroll, MD, MPH
University of California, San Francisco
San Francisco, California
Dr. Peter Carroll graduated with honors from Georgetown University School of Medicine, followed by general surgery training and urology residency at UCSF, and a fellowship in urologic oncology at Memorial-Sloan Kettering Cancer Center. He has taught at the UCSF Department of Urology since 1986, where he became the department chair in 1996. Under his leadership, the department has been consistently ranked one of the top urology departments in the country by U.S. News and World Report. The department has grown, serving an increasingly larger patient population, expanding its research programs, and attracting future leaders in the field for training. Under Dr. Carroll’s leadership, the department managed an average of over $10 million in research grants that put UCSF in first place for urology funding for five consecutive years. Dr. Carroll also established the UCSF Department of Urology’s comprehensive Tissue Core – a biobank of blood, urine and residual prostate, bladder and renal tissues for more than 6,000 consenting patients. In addition to his many accomplishments at UCSF, Dr. Carroll has authored or co-authored over 650 publications, is an active member of numerous professional medical societies, and is currently principal or co-investigator on numerous scientific studies. He is Past President of the American Board of Urology (2006-2008). His drive to perfect nerve-sparing prostatectomy has led to many technical innovations. His pioneering efforts for standardizing an active surveillance regimen has led to many patients postponing radical treatment while maintaining a low risk of cancer progression.